Background: Onychomycosis is a fungal infection of the nail apparatus that can be challenging to treat due to the modest efficacy of existing antifungal therapies and a high rate of relapse and recurrence.
Objectives: To investigate the efficacy and safety of efinaconazole 10% solution in pooled Phase III clinical trial participants with mild to moderate onychomycosis.
Methods: Phase III clinical trials data from NCT01008033 and NCT01007708 were pooled. Efficacy analysis for the primary and secondary outcome variables was conducted using the mITT population and analysed using Cochran-Mantel-Haenszel tests. Subgroup analysis was conducted for prognostic factors that may affect drug efficacy. Safety analysis was conducted on all recipients of a single drug dose.
Results: Efinaconazole 10% nail solution was superior to vehicle for all primary and secondary outcome measures assessed. Complete cure was 18.5% vs 4.7% P< 0.001 [mITT] and mycological cure was 56.3% vs 16.6%, P< 0.001 [mITT]. Complete or almost complete cure and treatment success were achieved in 27.7% and 47.2% compared to 7.9% and 18.2% with vehicle, respectively (P< 0.001 [mITT]). In all subgroups, efinaconazole 10% solution had statistically higher cures rates compared to vehicle. Higher complete cure rates were observed in women and individuals with mild disease (≤33% involvement), but not in any other subgroup assessed. Treatment associated adverse events in the efinaconazole 10% solution group were similar to vehicle and limited to local site reactions (2%).
Conclusions: The findings from this pooled analysis suggest that efinaconazole 10% solution may become the preferred topical agent for mild to moderate onychomycosis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efinaconazole 10% solution: a comprehensive review of its use in the treatment of onychomycosis.
Expert Opin Pharmacother
October 2024
Mediprobe Research Inc, London, ON, Canada.
Article Synopsis
- Onychomycosis is a fungal infection affecting nails, and while oral antifungals are the main treatment for severe cases, the topical solution efinaconazole (10%) is effective and safe for mild to moderate infections, approved for ages 6 and up.
- The literature review highlights efinaconazole's pharmacokinetics, safety, and effectiveness across different populations, including children, diabetics, and the elderly, showing no systemic side effects or drug interactions.
- Efinaconazole is particularly beneficial for certain groups, such as females, children, early-stage infections, and those with mild nail involvement, making it a viable option, especially in cases of terbinafine resistance.
Extended Use of Topical Efinaconazole Remains Safe and Can Provide Continuing Benefits for Dermatophyte Toenail Onychomycosis.
J Fungi (Basel)
August 2024
Mediprobe Research Inc., 645 Windermere Rd., London, ON N5X 2P1, Canada.
Article Synopsis
- Efinaconazole 10% is a topical treatment for onychomycosis (fungal nail infection) that has shown promising results in a 24-month study, indicating that longer treatment may enhance effectiveness.
- In a trial with 101 participants, those treated for 24 months had a mycological cure rate increase from 66.0% at 12 months to 71.7% at 24 months, alongside a rise in effective cure rates.
- Most side effects were mild and unrelated to systemic issues, suggesting that older patients and those with more severe infections can safely and effectively use the treatment without additional risks.
Article Synopsis
- Patients with toenail fungus (onychomycosis) can use nail polish without significantly affecting the treatment outcomes when using efinaconazole 10% solution.
- A review of clinical studies showed that both traditional and gel nail polishes did not hinder the effectiveness of efinaconazole, as participants experienced improvements in nail condition.
- Despite some degradation of traditional polish's appearance, gel polish remained unaffected, making it a viable option for those undergoing treatment.
Transungual Penetration and Antifungal Activity of Prescription and Over-the-Counter Topical Antifungals: Ex Vivo Comparison.
Dermatol Ther (Heidelb)
September 2024
Case Western Reserve University, Cleveland, OH, USA.
Introduction: Topical antifungals for toenail onychomycosis must penetrate the nail to deliver an inhibitory concentration of free drug to the site of infection. In two ex vivo experiments, we tested the ability of topical antifungals to inhibit growth of Trichophyton rubrum and Trichophyton mentagrophytes, the most common causative fungi in toenail onychomycosis.
Methods: Seven topical antifungals were tested: three U.
Impact of new antifungal medications on onychomycosis prescriptions and costs in Japan: A nationwide claims database study.
J Dermatol
September 2024
Center for Next Generation of Community Health, Chiba University Hospital, Chiba-shi, Chiba, Japan.
Article Synopsis
- Onychomycosis is a prevalent fungal nail infection in Japan, affecting about 5%-10% of the population, and this study analyzes prescription patterns and medical costs related to its treatment from 2014 to 2021.
- Efinaconazole, a topical antifungal launched in 2014, quickly became the most prescribed treatment, while prescriptions for the established oral medication terbinafine decreased significantly.
- The total medical costs for treating onychomycosis rose dramatically, surpassing 30 billion yen between 2019-2021, emphasizing the economic burden and the need for better adherence to treatment guidelines recommending oral antifungals.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!